Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Lowered by StockNews.com

Posted by Jessica Moore on Nov 13th, 2024

StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

Brainstorm Cell Therapeutics Stock Performance

BCLI stock opened at $1.18 on Tuesday. The company has a market capitalization of $6.28 million, a P/E ratio of -0.34 and a beta of 0.40. The company has a fifty day moving average price of $2.71 and a 200-day moving average price of $4.80. Brainstorm Cell Therapeutics has a 52-week low of $1.09 and a 52-week high of $11.89.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). During the same period in the prior year, the business earned ($4.05) EPS. As a group, sell-side analysts forecast that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.